RxDoctor Payments Data

Jason Oberdick, PA

Physician Assistant · Wexford, PANPI 1316027774

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $176,894 of the $205,962 with a category attached, or 85.9%. 29 manufacturers reported payments, led by Lilly USA, LLC at 38.2% of the total. Reporting peaked in 2022 at $60,927 and has fallen 91.4% since, to $5,247 in 2025. Among physician assistant clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$205,962in general payments, 2019–2025

Across 1,504 payments — averaging $136.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$79K
  • AbbVie$74K
  • Sanofi$31K
  • Regeneron Healthcare Solutions, Inc.$10K
  • Novartis$3K
  • Johnson & Johnson$2K
  • plus $8K from 23 others

What the payments were for

  • Consulting fees$3,4712%
  • Speaking & faculty fees$176,89486%
  • Travel & lodging$5,7103%
  • Food & beverage$19,58410%
  • Education$3030%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$205,962 in reported general payments places this provider in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$100,295
Medicare patients
597
Services billed
1,859

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TremfyaGuselkumab12$153,654
Cosentyx Sensoready (2 Pens)Secukinumab11$82,167
Dupixent PenDupilumab12$52,438
Clobetasol Propionate147$4,218
Doxycycline Hyclate99$2,473
Tacrolimus23$2,426
Azelaic Acid15$2,167
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc90$2,078
Metronidazole25$1,715
Betamethasone Dipropionate49$1,619
Triamcinolone Acetonide155$1,617
Minocycline Hcl21$1,390
Ketoconazole71$1,183
Clindamycin Phosphate34$1,093
Fluorouracil17$998

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$2,006$153,65412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Wexford

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →